CVRx price target raised to $32 from $21 at Lake Street

Lake Street raised the firm’s price target on CVRx to $32 from $21 and keeps a Buy rating on the shares after the FDA approved an expanded label for Barostim to include the primary endpoint results, the 6, 12, and 24 month symptomatic data, the win ratio, and the all-cause mortality data. The new label is “significantly more favorable than the prior label” and should expand the patient pool and drive faster adoption of Barostim, the analyst tells investors.